Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dry cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    53 result(s) found for: Dry cell. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2018-000348-24 Sponsor Protocol Number: CVB2018-1 Start Date*: 2018-06-11
    Sponsor Name:Department of Otorhinolaryngology, Head and Neck Surgery
    Full Title: Mesenchymal stem cells for radiation-induced hyposalivation and xerostomia in previous head and neck cancer patients (MESRIX-II)
    Medical condition: The trial will include participants with Xerostomia (International Classification of Diseases-10: DQ 838A) who have been treated with raditherapy for a head and neck cancer prevoiusly.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10013781 Dry mouth PT
    20.0 10017947 - Gastrointestinal disorders 10048223 Xerostomia LLT
    20.0 100000004865 10039420 Salivary gland therapeutic procedures HLT
    20.0 10017947 - Gastrointestinal disorders 10039404 Salivary gland conditions HLGT
    21.1 10017947 - Gastrointestinal disorders 10039390 Salivary gland atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001642-18 Sponsor Protocol Number: WP3 Start Date*: 2019-12-05
    Sponsor Name:Department of Ophthalmology, Rigshospitalet-Glostrup
    Full Title: Effect on the ocular surface when treating glaucoma with eye drops: an investigation of the conjunctival goblet cells
    Medical condition: Open angular glaucoma and ocular hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004349-29 Sponsor Protocol Number: 01-10-2014 Start Date*: 2015-04-01
    Sponsor Name:Rigshospitalet
    Full Title: Mesenchymal stem cells for radiation-induced xerostomia (MESRIX) in previous HPV-positive oropharyngeal head and neck cancer patients
    Medical condition: The study will include participants with xerostomi (International Classification of Diseases-10: DQ 838A) and oropharyngeal cancer (DC 10).
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10031103 Oropharyngeal cancer stage unspecified LLT
    17.1 100000004856 10048223 Xerostomia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-024425-20 Sponsor Protocol Number: Esperanz-002 Start Date*: 2011-03-14
    Sponsor Name:Leiden University Medical Centre
    Full Title: Phase III Randomized Double-blind Cross-over trial of Supersaturated Calcium-phosphate rinse (Caphosol®) versus NaCl 0.9% in the relief of Oral Mucositis in renal cell carcinoma, hepatocellular car...
    Medical condition: oral mucositis in renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumor
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028127 Mucositis LLT
    12.1 10042128 Stomatitis LLT
    12.1 10042128 Stomatitis PT
    12.1 10031009 Oral pain LLT
    12.1 10031009 Oral pain PT
    12.1 10013911 Dysgeusia LLT
    12.1 10013911 Dysgeusia PT
    12.1 10013950 Dysphagia LLT
    12.1 10013950 Dysphagia PT
    12.1 10013781 Dry mouth LLT
    12.1 10013781 Dry mouth PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003774-27 Sponsor Protocol Number: BC-180-12 Start Date*: 2014-01-20
    Sponsor Name:AlgiPharma AS
    Full Title: An open label, randomised, two-way crossover scintigraphic study to investigate lung deposition of radiolabelled OligoG delivered as a dry powder and as a nebulised solution in cystic fibrosis pati...
    Medical condition: Cystic fibrosis (CF) is an autosomal, recessive inheritable disease caused by a homozygote defect at the long arm of Chromosome 7. This mutation causes absence or defect of the cystic fibrosis tran...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003856-19 Sponsor Protocol Number: CVB2018-2 Start Date*: 2019-01-09
    Sponsor Name:Department of Otorhinolaryngology, Head and Neck Surgery and Audiology. Rigshospitalet, University Hospital of Cph, DK
    Full Title: A Phase I Open Label Study Evaluating the Safety and Feasibility of Allogeneic Mesenchymal stem cells for radiation-induced hyposalivation and xerostomia in previous oropharyngeal patients
    Medical condition: The trial will include participants with Xerostomia ( International Classification of Diseases-10: DQ 838A)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10048223 Xerostomia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001475-33 Sponsor Protocol Number: COLVID-19 Start Date*: 2020-04-10
    Sponsor Name:DIPARTIMENTO DI MEDICINA, UNIVERSITà DI PERUGIA
    Full Title: Treatment with COLchicine of patients affected by COVID-19: a Pilot Study
    Medical condition: Study population: patients with COVID-19 pneumonia with oxygen saturation deficiency and requiring hospitalization assistance.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10053983 Corona virus infection LLT
    23.0 10021881 - Infections and infestations 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001561-88 Sponsor Protocol Number: CICL670ATRO4 Start Date*: 2016-04-14
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation
    Medical condition: -Iron overload
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-005332-30 Sponsor Protocol Number: ACT16845 Start Date*: 2021-09-27
    Sponsor Name:SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
    Full Title: A Phase 1/2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR- 707) combined with cemiplimab for the treatment of participants with adva...
    Medical condition: Advanced unresectable or metastatic skin cancers
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041834 Squamous cell carcinoma of skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015558-40 Sponsor Protocol Number: ABACEPT1 Start Date*: 2010-07-28
    Sponsor Name:University Medical Center Groningen
    Full Title: Abatacept treatment in patients with primary Sjögren’s syndrome
    Medical condition: Sjögren’s syndrome (SS) is a chronic, systemic, lymphoproliferative autoimmune disease affecting the exocrine glands. The salivary and lacrimal glands are most commonly affected, resulting in dry m...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10040767 Sjogren's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002016-28 Sponsor Protocol Number: 20040118 Start Date*: 2005-01-04
    Sponsor Name:Amgen
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduct...
    Medical condition: Oral mucositis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004856 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000712-27 Sponsor Protocol Number: TMC125-C229 Start Date*: 2005-07-15
    Sponsor Name:Tibotec Pharmaceuticals Limited
    Full Title: An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks.
    Medical condition: HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005034-20 Sponsor Protocol Number: 228-13/06 Start Date*: 2007-03-08
    Sponsor Name:Klinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf
    Full Title: Doppelblinde, prospektiv-randomisierte, intraindividuell-halbseitenvergleichende Studie zur klinischen Wirksamkeit von Verrumal® Lsg. bei aktinischen Keratosen gegen Vehikel: Investigator-initiiert...
    Medical condition: Actinic keratosis is a precancerous skin growth usually caused by sun exposure. Symptoms: Rough and dry textured skin lesion, macule, patch, or growth on the skin Located on sun-exposed areas. Acti...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000614 Actinic keratosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000674-20 Sponsor Protocol Number: SSAT 029 Start Date*: 2008-05-22
    Sponsor Name:St Stephen's Aids Trust
    Full Title: A phase III, double blind, multi centre, randomised placebo controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing Central Nervous System (CN...
    Medical condition: HIV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003145-13 Sponsor Protocol Number: TMC125-C206 Start Date*: 2006-07-06
    Sponsor Name:Tibotec Pharmaceuticals Limited
    Full Title: A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected O...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    9.0 10020192 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001287-23 Sponsor Protocol Number: TMC125-C217 Start Date*: 2006-06-13
    Sponsor Name:Tibotec Pharmaceuticals Limited
    Full Title: An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216).
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002122-20 Sponsor Protocol Number: 0460 Start Date*: 2018-06-06
    Sponsor Name:Dean of the Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg Prof. Dr. med. Markus F. Neurath
    Full Title: Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma (IMPORTANCE)
    Medical condition: Metastatic head and neck squamous cell carcinoma (LLT, 20.1) 10060121 (LLT, 20.1)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006300-27 Sponsor Protocol Number: MC-ASP.6/INF Start Date*: 2009-08-12
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphoblastic leukaemia - Phase II Clinical Trial -
    Medical condition: Acute lymphoblastic leukaemia (ALL) is a clonal disease resulting from genetic mutations and transformation of a single early progenitor lymphoid cell. Uncontrolled expansion of leukaemic blasts in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019645-25 Sponsor Protocol Number: SPD602-201 Start Date*: 2010-07-19
    Sponsor Name:Shire Development LLC
    Full Title: A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation T...
    Medical condition: Patients with transfusional iron overload due to hereditary anemias such as sickle cell disease, β-thalassemia and Diamond-Blackfan anemia; acquired anemias such as Myelodysplastic Syndrome and oth...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10065974 Chronic iron overload LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005675-16 Sponsor Protocol Number: FBS0701-CTP-16 Start Date*: 2012-05-15
    Sponsor Name:FERROKIN BIOSCIENCES INC.
    Full Title: A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two FBS0701 Doses in the Treatment of Chronic Iron Overlo...
    Medical condition: Patients with transfusional iron overload, with the following primary diagnosis:hereditary anemia (such as sickle cell disease),β-thalassemia and Diamond Blackfan anemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 15 11:00:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA